Global Hemoporfin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Hemoporfin market size was valued at US$ 103 million in 2025 and is forecast to a readjusted size of US$ 496 million by 2032 with a CAGR of 24.4% during review period.
In 2025, global Hemoporfin production reached approximately 850 000 units.Hemoporfin, chemically known as Hematoporphyrin Monomethyl Ether (HMME) and marketed under the brand name Fumeida, is a second-generation monomeric porphyrin photodynamic therapeutic drug independently developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical in China. It is classified as a national Class 1.1 chemical innovative drug. As the world’s first targeted therapeutic drug specifically designed for port-wine stains (PWS), it is positioned as a highly vascular-targeted photosensitizer with strong selectivity.
Hemoporfin is a photosensitizer used in photodynamic therapy (PDT), primarily indicated for the treatment of vascular skin conditions such as port-wine stains, and demonstrates strong technological barriers and differentiated advantages in the medical aesthetics and dermatology markets. With the growing demand for aesthetic medicine and the increasing refinement of dermatological treatments, the clinical application of photodynamic therapy is expanding, providing a stable foundation for market demand. From a competitive landscape perspective, traditional treatment methods such as laser therapy still dominate the market, but they have limitations in certain refractory or large-area lesions. In comparison, hemoporfin offers better selectivity and efficacy, giving it advantages as an alternative or complementary therapy in specific indications. On the policy side, the medical aesthetics and dermatology sectors are becoming increasingly regulated. Limited reimbursement coverage means many patients rely on out-of-pocket payments, leading to higher price sensitivity. At the same time, requirements related to healthcare institution qualifications and equipment availability create barriers to its broader adoption. From a competitive standpoint, although there are relatively few products in the photodynamic therapy field, potential entrants and alternative technologies (such as new laser devices) continue to emerge, intensifying competition. Therefore, the future market performance of hemoporfin will depend on the expansion of its indications, the accumulation of clinical evidence, and its overall balance in efficacy, safety, and treatment cost, as well as its promotion capabilities and standardized use across healthcare institutions.
This report is a detailed and comprehensive analysis for global Hemoporfin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hemoporfin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hemoporfin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hemoporfin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hemoporfin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hemoporfin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hemoporfin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Hemoporfin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
5 mg/vial
10 mg/vial
Market segment by Dosage Form
Injection
Lyophilized Powder for Injection
Market segment by Release Type
Immediate-release (IR)
Controlled-release (CR)
Market segment by Application
Dermatology
Hemangioma Specialty Clinic
Department of Aesthetic and Plastic Surgery
Others
Major players covered
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hemoporfin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hemoporfin, with price, sales quantity, revenue, and global market share of Hemoporfin from 2021 to 2026.
Chapter 3, the Hemoporfin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hemoporfin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Hemoporfin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hemoporfin.
Chapter 14 and 15, to describe Hemoporfin sales channel, distributors, customers, research findings and conclusion.